FDA Becomes An Agency Of “Directorates” Under Hamburg’s Reorganization
This article was originally published in The Tan Sheet
Executive Summary
Commissioner Margaret Hamburg’s structural reorganization of FDA leaves the current leadership of the agency’s centers intact, but adds a new layer of management and accountability between the medical product center directors and the commissioner’s office.
You may also be interested in...
Hamburg, Senior Panel Continue “Rethinking” FDA Organization
Commissioner Margaret Hamburg awaits recommendations from a panel of senior agency officials on how to ensure FDA’s centers support Office of Regulatory Affairs’ activities without duplication.
Hamburg, Senior Panel Continue “Rethinking” FDA Organization
Commissioner Margaret Hamburg awaits recommendations from a panel of senior agency officials on how to ensure FDA’s centers support Office of Regulatory Affairs’ activities without duplication.
Hamburg, Senior Panel Continue “Rethinking” FDA Organization
Commissioner Margaret Hamburg awaits recommendations from a panel of senior agency officials on how to ensure FDA’s centers support Office of Regulatory Affairs’ activities without duplication.